PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

cimetidine Side Effects

The reactions most often reported to the FDA for cimetidine (also sold as Tagamet), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

9,140
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 1998 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of cimetidine come from 9,140 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 9,140 reports to the FDA Adverse Event Reporting System (FAERS) for cimetidine (Tagamet): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

9,140

Reports Mentioning Death

1,168

12.8% of reports — not proof the medicine caused the death

Hospitalizations

3,377

36.9% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

CHRONIC KIDNEY DISEASE
1,264
ACUTE KIDNEY INJURY
710
RENAL FAILURE
694
NAUSEA
681
FATIGUE
598
DYSPNOEA
504
VOMITING
483
DIARRHOEA
440
PAIN
432
DEATH
399
DIZZINESS
386
HEADACHE
371
GASTROOESOPHAGEAL REFLUX DISEASE
370
ANXIETY
348
END STAGE RENAL DISEASE
347
DEPRESSION
343
HYPERTENSION
335
ASTHENIA
318

Who Reports Side Effects

Gender Distribution

Female 5,379 (65%)
Male 2,855 (35%)
Unknown 20

Age Distribution

0-17 165 (3%)
18-44 1,019 (17%)
45-64 2,596 (43%)
65-74 1,328 (22%)
75+ 872 (15%)

Reporting Trend by Year

1998 2025

Reactions in Death Reports

Top reactions reported in 1,168 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 399
FATIGUE 141
CHRONIC KIDNEY DISEASE 121
NAUSEA 120
RENAL FAILURE 109
DYSPNOEA 102
PNEUMONIA 94
ACUTE KIDNEY INJURY 93
VOMITING 93
PAIN 92
END STAGE RENAL DISEASE 79
DISEASE PROGRESSION 75
PYREXIA 74
ASTHENIA 70
DIARRHOEA 70
CONSTIPATION 67
ANAEMIA 59
COUGH 58
RESPIRATORY FAILURE 56

Reactions in Hospitalization Reports

Top reactions in 3,377 reports where hospitalization was an outcome.

Reaction Reports
DYSPNOEA 250
NAUSEA 249
VOMITING 248
FATIGUE 239
ACUTE KIDNEY INJURY 229
RENAL FAILURE 223
PNEUMONIA 219
CHRONIC KIDNEY DISEASE 212
HYPERTENSION 212
DIARRHOEA 204
ABDOMINAL PAIN 191
PYREXIA 182
DEPRESSION 177
PAIN 174
FALL 161
ASTHENIA 155
DIZZINESS 155
CHEST PAIN 150
ANXIETY 144

Compare cimetidine vs alosetron →

What the FAERS Data Reveals About cimetidine Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 9,140 voluntary reports linked to cimetidine and its brand equivalents (Tagamet), spanning 1998 through 2025. Of those, 1,168 (12.8%) listed death as an outcome and 3,377 (36.9%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 65% were female and 35% male; age distribution skews toward 45-64, with 2,596 reports in that bracket. The single most reported reaction is chronic kidney disease with 1,264 submissions, followed by acute kidney injury and renal failure.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.